cinacalcet hydrochloride

Known as: Hydrochloride, Cinacalcet, 1-Naphthalenemethanamine, a-methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-,(aR)-, Hydrochloride, Alpha-methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethanamine, (alphaR)-hydrochloride 
The orally bioavailable hydrochloride salt of the calcimimetic cinacalcet. Cinacalcet increases the sensitivity of calcium-sensing receptors on chief… (More)
National Institutes of Health

Related topics

Related topics

11 relations

Narrower (1)

AMG 073

Broader (1)

Calcimimetic Agents
In Bloodagonistsanalogs & derivativesantagonists & inhibitors
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
BACKGROUND Patients with kidney disease have disordered bone and mineral metabolism, including elevated serum concentrations of… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients.
Secondary hyperparathyroidism (SHPT) affects a significant number of hemodialysis patients, and metabolic disturbances associated… (More)
  • table 1
  • table 2
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.
BACKGROUND AND OBJECTIVES Fibroblast growth factor-23 (FGF23) levels are elevated in ESRD and have been associated with adverse… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Review
2009
Review
2009
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
Cinacalcet hydrochloride (cinacalcet) is a calcimimetic approved for the treatment of secondary hyperparathyroidism in patients… (More)
  • table I
  • table II
  • table III
  • figure 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.
BACKGROUND Management of inoperable parathyroid carcinoma presents a challenge because until recently, effective medical therapy… (More)
Is this relevant?
2006
2006
Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride.
An underrecognized side effect of long-term lithium carbonate therapy is hyperparathyroidism with associated hypercalcemia and… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.
Calcimimetics increase the sensitivity of parathyroid calcium-sensing receptors to extracellular calcium, thereby reducing PTH… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.
BACKGROUND Secondary hyperparathyroidism develops early in patients with chronic kidney disease (CKD). Clinical guidelines from… (More)
Is this relevant?
2005
2005
Cinacalcet hydrochloride (Sensipar).
Currently, >300,000 patients with end-stage renal disease require dialysis. Secondary hyperparathyroidism is a serious… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
BACKGROUND Treatment of secondary hyperparathyroidism with vitamin D and calcium in patients receiving dialysis is often… (More)
Is this relevant?